All In Biotech

NDA 208276 · United Therap

Remodulin

Treprostinil · Intravenous, Subcutaneous

OrphanDiscontinued

Last checked: Nov 20, 2026Latest source record: Jul 30, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Jul 30, 2018

Approved uses

1

Original approval plus efficacy supplements

Registered trials

129

42 Phase 3, 15 recruiting

FAERS reports

64,707

41,543 serious, 9,004 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • REMODULIN · TREPROSTINIL 100MG/20ML (5MG/ML) · SOLUTION, INTRAVENOUS, SUBCUTANEOUS · Discontinued
  • REMODULIN · TREPROSTINIL 20MG/20ML (1MG/ML) · SOLUTION, INTRAVENOUS, SUBCUTANEOUS · Discontinued
  • REMODULIN · TREPROSTINIL 200MG/20ML (10MG/ML) · SOLUTION, INTRAVENOUS, SUBCUTANEOUS · Discontinued
  • REMODULIN · TREPROSTINIL 50MG/20ML (2.5MG/ML) · SOLUTION, INTRAVENOUS, SUBCUTANEOUS · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Treprostinil" as an intervention, any sponsor and status, largest first.

All 129 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea9,869
  • headache7,151
  • diarrhoea6,878
  • nausea6,178
  • infusion site pain5,787
  • death5,212
  • fatigue4,057
  • dizziness3,833
  • vomiting3,379
  • infusion site erythema3,348
  • pain in extremity2,962
  • hypotension2,833

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200431
200558
200686
200739
200831
200964
2010889
20111,616
2012642
2013998
20144,571
20155,443
20164,819
20174,835
20185,286
20194,950
20204,256
20214,001
20224,300
20235,013
20244,579
20254,856
20263,344

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Remodulin (Treprostinil Sodium)

2024 spending

$13.5M

Beneficiaries

110

1,228 claims

Per beneficiary

$122,999

$437.45 per unit

View as table
YearSpending
2020$5,233,310
2021$6,905,569
2022$10,337,855
2023$11,819,879
2024$13,529,903

Part B: Remodulin* (Treprostinil Sodium*) · HCPCS J3285

2024 spending

$122M

Beneficiaries

909

12,831 claims

Per beneficiary

$133,774

2024 ASP limit $55.56 per unit

View as table
YearSpending
2020$163,468,435
2021$155,903,548
2022$130,449,989
2023$126,521,237
2024$121,601,006

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 116 on PubMed

Sponsor: United Therap

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.